JP4709758B2 - 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 - Google Patents

呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 Download PDF

Info

Publication number
JP4709758B2
JP4709758B2 JP2006523677A JP2006523677A JP4709758B2 JP 4709758 B2 JP4709758 B2 JP 4709758B2 JP 2006523677 A JP2006523677 A JP 2006523677A JP 2006523677 A JP2006523677 A JP 2006523677A JP 4709758 B2 JP4709758 B2 JP 4709758B2
Authority
JP
Japan
Prior art keywords
methyl
indole
acetic acid
phenoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006523677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502804A (ja
JP2007502804A5 (OSRAM
Inventor
ロジャー・ビクター・ボナート
アンソニー・ロナルド・クック
ティモシー・ジョン・ルーカー
ルクサナ・タスニーム・モハンメド
スティーブン・トム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007502804A publication Critical patent/JP2007502804A/ja
Publication of JP2007502804A5 publication Critical patent/JP2007502804A5/ja
Application granted granted Critical
Publication of JP4709758B2 publication Critical patent/JP4709758B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/36Oxygen atoms in position 3, e.g. adrenochrome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006523677A 2003-08-18 2004-08-16 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 Expired - Fee Related JP4709758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302232A SE0302232D0 (sv) 2003-08-18 2003-08-18 Novel Compounds
SE0302232-4 2003-08-18
PCT/GB2004/003502 WO2005019171A1 (en) 2003-08-18 2004-08-16 Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases

Publications (3)

Publication Number Publication Date
JP2007502804A JP2007502804A (ja) 2007-02-15
JP2007502804A5 JP2007502804A5 (OSRAM) 2007-09-27
JP4709758B2 true JP4709758B2 (ja) 2011-06-22

Family

ID=28450248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523677A Expired - Fee Related JP4709758B2 (ja) 2003-08-18 2004-08-16 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体

Country Status (18)

Country Link
US (1) US7709521B2 (OSRAM)
EP (1) EP1656347B1 (OSRAM)
JP (1) JP4709758B2 (OSRAM)
AR (1) AR045462A1 (OSRAM)
AT (1) ATE484494T1 (OSRAM)
CY (1) CY1110977T1 (OSRAM)
DE (1) DE602004029580D1 (OSRAM)
DK (1) DK1656347T3 (OSRAM)
ES (1) ES2352201T3 (OSRAM)
MY (1) MY143367A (OSRAM)
PL (1) PL1656347T3 (OSRAM)
PT (1) PT1656347E (OSRAM)
SA (1) SA04250255B1 (OSRAM)
SE (1) SE0302232D0 (OSRAM)
SI (1) SI1656347T1 (OSRAM)
TW (1) TW200510303A (OSRAM)
UY (1) UY28473A1 (OSRAM)
WO (1) WO2005019171A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
ES2304010T3 (es) 2004-03-11 2008-09-01 Actelion Pharmaceuticals Ltd. Derivados de tetrahidropiridoindol.
CN101084190B (zh) 2004-12-27 2011-01-26 埃科特莱茵药品有限公司 作为crth2受体拮抗剂的2,3,4,9-四氢-1h-咔唑衍生物
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
US7741360B2 (en) * 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
PL2037967T3 (pl) 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
CA2658986C (en) 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
SI2133332T1 (sl) 2007-04-11 2014-02-28 Kissei Pharmaceutical Co., Ltd. (aza)indolinski derivat in njegova uporaba v medicinske namene
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
EP2327693B9 (en) 2007-12-14 2012-10-24 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
JPWO2010074244A1 (ja) * 2008-12-25 2012-06-21 大正製薬株式会社 イソキノリン誘導体
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
BR112012000353B1 (pt) * 2009-07-06 2020-06-02 Astrazeneca Ab Composto de fórmula markush, uso do composto, processos de reação com agente de acetilação e processo para preparação de um composto
AU2011215638B2 (en) 2010-02-11 2016-04-28 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
CN103119024A (zh) 2010-06-23 2013-05-22 大正制药株式会社 异喹啉衍生物
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CA2867901A1 (en) 2012-03-21 2013-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素d2受體調節劑之用途
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び/又は、治療するためのptgdr−1及び/又はptgdr−2アンタゴニスト
HK1256553A1 (zh) 2015-07-30 2019-09-27 The Trustees Of The University Of Pennsylvania 用於检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
CN121021491A (zh) * 2020-10-28 2025-11-28 盐野义制药株式会社 具有抗病毒活性的酰胺衍生物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AU6254294A (en) 1993-02-24 1994-09-14 Merck & Co., Inc. Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
ZA9811672B (en) 1997-12-19 2000-06-19 Lilly Co Eli Hypoglycemic imidazoline compounds.
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
MXPA02006338A (es) 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
EP1501826B1 (en) * 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituted indoles as alpha-1 agonists
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
EP1675826A1 (en) 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
US7741360B2 (en) * 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
MX2008015501A (es) 2006-06-08 2009-02-18 Neurokey As Uso de agonistas del receptor de canabinoide como farmacos inductores de hipotermia para el tratamiento de isquemia.
JP5237938B2 (ja) 2006-06-28 2013-07-17 サノフイ 新規なcxcr2阻害剤

Also Published As

Publication number Publication date
WO2005019171A1 (en) 2005-03-03
ATE484494T1 (de) 2010-10-15
SE0302232D0 (sv) 2003-08-18
DK1656347T3 (da) 2011-01-10
DE602004029580D1 (de) 2010-11-25
JP2007502804A (ja) 2007-02-15
EP1656347B1 (en) 2010-10-13
MY143367A (en) 2011-04-29
SI1656347T1 (sl) 2011-01-31
PT1656347E (pt) 2010-12-09
US7709521B2 (en) 2010-05-04
PL1656347T3 (pl) 2011-02-28
EP1656347A1 (en) 2006-05-17
TW200510303A (en) 2005-03-16
CY1110977T1 (el) 2015-06-11
US20060264444A1 (en) 2006-11-23
AR045462A1 (es) 2005-10-26
UY28473A1 (es) 2005-03-31
ES2352201T3 (es) 2011-02-16
SA04250255B1 (ar) 2009-02-25

Similar Documents

Publication Publication Date Title
JP4709758B2 (ja) 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体
JP4541361B2 (ja) 新規3位硫黄置換インドール
JP2007512299A (ja) 呼吸器系疾患の処置に有用な1−酢酸−インドール、−インダゾールおよび−ベンズイミダゾール誘導体
JP4588018B2 (ja) 新規化合物
JP2009538289A (ja) ビアリールまたはヘテロアリール置換インドール
HK1090635B (en) Substituted 3-sulfur indoles
HK1126773B (en) Use of 3-phenylthio-1h-indole-1-acetic acid derivatives as modulators of crth2 receptor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees